TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hydrix Limited ( (AU:HYD) ) has shared an update.
Hydrix Limited reported consecutive profitable quarters for its services division, driven by improved margins, increased billable utilization, and reduced operating costs. The company achieved a 37% increase in contract sales orders, with significant contributions from international clients and cardiac monitoring products. The recent FDA clearance for Gyder Surgical’s Hip Navigation System underscores Hydrix’s expertise in medical device development and boosts its venture investments. The company anticipates continued sales momentum and revenue growth, supported by a robust sales pipeline and strategic international market engagements.
More about Hydrix Limited
Hydrix Limited operates in the medical technology sector, providing specialized engineering and program management services. The company focuses on cardiac monitoring products and new product development, with a significant presence in international markets, particularly Europe and the USA.
YTD Price Performance: 140.0%
Average Trading Volume: 2,244,726
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$6.55M
For an in-depth examination of HYD stock, go to TipRanks’ Stock Analysis page.